|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: BOD1L1 |
Gene summary for BOD1L1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | BOD1L1 | Gene ID | 259282 |
| Gene name | biorientation of chromosomes in cell division 1 like 1 | |
| Gene Alias | BOD1L | |
| Cytomap | 4p15.33 | |
| Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | Q8NFC6 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 259282 | BOD1L1 | HTA11_3410_2000001011 | Human | Colorectum | AD | 2.09e-02 | -3.03e-01 | 0.0155 |
| 259282 | BOD1L1 | HTA11_696_2000001011 | Human | Colorectum | AD | 9.81e-03 | -2.35e-01 | -0.1464 |
| 259282 | BOD1L1 | HTA11_99999974143_84620 | Human | Colorectum | MSS | 3.75e-04 | -3.07e-01 | 0.3005 |
| 259282 | BOD1L1 | A015-C-203 | Human | Colorectum | FAP | 1.53e-18 | 2.53e-01 | -0.1294 |
| 259282 | BOD1L1 | A015-C-204 | Human | Colorectum | FAP | 2.87e-04 | 1.97e-01 | -0.0228 |
| 259282 | BOD1L1 | A014-C-040 | Human | Colorectum | FAP | 4.17e-02 | 2.77e-01 | -0.1184 |
| 259282 | BOD1L1 | A002-C-201 | Human | Colorectum | FAP | 1.70e-06 | 6.80e-02 | 0.0324 |
| 259282 | BOD1L1 | A001-C-119 | Human | Colorectum | FAP | 1.19e-15 | 6.40e-01 | -0.1557 |
| 259282 | BOD1L1 | A001-C-108 | Human | Colorectum | FAP | 2.83e-15 | 4.94e-01 | -0.0272 |
| 259282 | BOD1L1 | A002-C-205 | Human | Colorectum | FAP | 1.41e-18 | 3.02e-01 | -0.1236 |
| 259282 | BOD1L1 | A001-C-104 | Human | Colorectum | FAP | 2.61e-07 | 4.38e-01 | 0.0184 |
| 259282 | BOD1L1 | A015-C-005 | Human | Colorectum | FAP | 7.96e-04 | 3.65e-01 | -0.0336 |
| 259282 | BOD1L1 | A015-C-006 | Human | Colorectum | FAP | 6.03e-18 | 4.44e-01 | -0.0994 |
| 259282 | BOD1L1 | A015-C-106 | Human | Colorectum | FAP | 3.89e-07 | 3.48e-01 | -0.0511 |
| 259282 | BOD1L1 | A002-C-114 | Human | Colorectum | FAP | 6.91e-15 | 2.52e-01 | -0.1561 |
| 259282 | BOD1L1 | A015-C-104 | Human | Colorectum | FAP | 4.34e-30 | 4.77e-01 | -0.1899 |
| 259282 | BOD1L1 | A001-C-014 | Human | Colorectum | FAP | 1.54e-06 | 2.16e-01 | 0.0135 |
| 259282 | BOD1L1 | A002-C-016 | Human | Colorectum | FAP | 1.93e-12 | 1.51e-01 | 0.0521 |
| 259282 | BOD1L1 | A015-C-002 | Human | Colorectum | FAP | 6.28e-07 | 1.95e-01 | -0.0763 |
| 259282 | BOD1L1 | A001-C-007 | Human | Colorectum | CRC | 7.06e-05 | 5.68e-01 | 0.1899 |
| Page: 1 2 3 4 5 6 7 8 9 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0010563 | Colorectum | AD | negative regulation of phosphorus metabolic process | 130/3918 | 442/18723 | 1.26e-05 | 2.76e-04 | 130 |
| GO:0045936 | Colorectum | AD | negative regulation of phosphate metabolic process | 129/3918 | 441/18723 | 1.81e-05 | 3.76e-04 | 129 |
| GO:0016311 | Colorectum | AD | dephosphorylation | 123/3918 | 417/18723 | 1.84e-05 | 3.82e-04 | 123 |
| GO:0006470 | Colorectum | AD | protein dephosphorylation | 88/3918 | 281/18723 | 2.56e-05 | 4.89e-04 | 88 |
| GO:0035303 | Colorectum | AD | regulation of dephosphorylation | 46/3918 | 128/18723 | 6.20e-05 | 1.04e-03 | 46 |
| GO:0035304 | Colorectum | AD | regulation of protein dephosphorylation | 33/3918 | 90/18723 | 4.23e-04 | 4.77e-03 | 33 |
| GO:0010921 | Colorectum | AD | regulation of phosphatase activity | 30/3918 | 84/18723 | 1.24e-03 | 1.09e-02 | 30 |
| GO:0043666 | Colorectum | AD | regulation of phosphoprotein phosphatase activity | 21/3918 | 58/18723 | 5.25e-03 | 3.47e-02 | 21 |
| GO:0035308 | Colorectum | AD | negative regulation of protein dephosphorylation | 14/3918 | 34/18723 | 5.86e-03 | 3.69e-02 | 14 |
| GO:00105632 | Colorectum | MSS | negative regulation of phosphorus metabolic process | 118/3467 | 442/18723 | 1.18e-05 | 2.77e-04 | 118 |
| GO:00459362 | Colorectum | MSS | negative regulation of phosphate metabolic process | 117/3467 | 441/18723 | 1.74e-05 | 3.84e-04 | 117 |
| GO:00353032 | Colorectum | MSS | regulation of dephosphorylation | 41/3467 | 128/18723 | 1.64e-04 | 2.33e-03 | 41 |
| GO:00353042 | Colorectum | MSS | regulation of protein dephosphorylation | 30/3467 | 90/18723 | 5.58e-04 | 6.19e-03 | 30 |
| GO:00064702 | Colorectum | MSS | protein dephosphorylation | 73/3467 | 281/18723 | 1.15e-03 | 1.12e-02 | 73 |
| GO:00163112 | Colorectum | MSS | dephosphorylation | 101/3467 | 417/18723 | 1.98e-03 | 1.70e-02 | 101 |
| GO:00513461 | Colorectum | MSS | negative regulation of hydrolase activity | 92/3467 | 379/18723 | 2.85e-03 | 2.22e-02 | 92 |
| GO:00109212 | Colorectum | MSS | regulation of phosphatase activity | 26/3467 | 84/18723 | 4.06e-03 | 2.95e-02 | 26 |
| GO:00436662 | Colorectum | MSS | regulation of phosphoprotein phosphatase activity | 19/3467 | 58/18723 | 6.69e-03 | 4.38e-02 | 19 |
| GO:00163113 | Colorectum | FAP | dephosphorylation | 95/2622 | 417/18723 | 7.07e-07 | 3.32e-05 | 95 |
| GO:00064704 | Colorectum | FAP | protein dephosphorylation | 69/2622 | 281/18723 | 1.47e-06 | 6.39e-05 | 69 |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| BOD1L1 | SNV | Missense_Mutation | novel | c.5909N>T | p.Pro1970Leu | p.P1970L | Q8NFC6 | protein_coding | tolerated(0.48) | benign(0) | TCGA-A2-A0EM-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD |
| BOD1L1 | SNV | Missense_Mutation | c.2668N>C | p.Glu890Gln | p.E890Q | Q8NFC6 | protein_coding | deleterious(0) | probably_damaging(0.984) | TCGA-A7-A26H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | PD | |
| BOD1L1 | SNV | Missense_Mutation | novel | c.917N>T | p.Asp306Val | p.D306V | Q8NFC6 | protein_coding | deleterious(0) | possibly_damaging(0.843) | TCGA-A7-A3RF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | PD |
| BOD1L1 | SNV | Missense_Mutation | c.1459N>C | p.Glu487Gln | p.E487Q | Q8NFC6 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-A8-A06U-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| BOD1L1 | SNV | Missense_Mutation | c.6967N>C | p.Asp2323His | p.D2323H | Q8NFC6 | protein_coding | deleterious(0) | probably_damaging(0.96) | TCGA-A8-A09I-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | SD | |
| BOD1L1 | SNV | Missense_Mutation | c.9023N>C | p.Arg3008Thr | p.R3008T | Q8NFC6 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| BOD1L1 | SNV | Missense_Mutation | c.398N>A | p.Arg133Gln | p.R133Q | Q8NFC6 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AC-A5XU-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | letrozole | SD | |
| BOD1L1 | SNV | Missense_Mutation | novel | c.2413G>T | p.Asp805Tyr | p.D805Y | Q8NFC6 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| BOD1L1 | SNV | Missense_Mutation | rs150805259 | c.3554N>A | p.Arg1185His | p.R1185H | Q8NFC6 | protein_coding | tolerated(0.06) | benign(0.006) | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| BOD1L1 | SNV | Missense_Mutation | c.2524N>A | p.Ser842Thr | p.S842T | Q8NFC6 | protein_coding | deleterious(0.03) | benign(0.159) | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |